164 related articles for article (PubMed ID: 6285154)
1. An intrauterine progesterone contraceptive system (52 mg) used in pre- and peri-menopausal patients with endometrial hyperplasia.
Volpe A; Botticelli A; Abrate M; Dalla Vecchia E; Mantovani M; Carani C; Grasso A; Mazza V; Di Renzo GC
Maturitas; 1982 Apr; 4(1):73-9. PubMed ID: 6285154
[TBL] [Abstract][Full Text] [Related]
2. Endocrinological features and endometrial morphology in climacteric women receiving hormone replacement therapy.
Grasso A; Baraghini F; Barbieri C; Dalla Vecchia E; Previdi AM; Di Renzo GC; Volpe A
Maturitas; 1982 Apr; 4(1):19-26. PubMed ID: 6285153
[TBL] [Abstract][Full Text] [Related]
3. Hormonal evaluation of the intrauterine progesterone contraceptive system.
Bryand-Greenwood GD; Greenwood FC; Hale RW; Morishige WK
J Clin Endocrinol Metab; 1977 Apr; 44(4):721-7. PubMed ID: 849982
[TBL] [Abstract][Full Text] [Related]
4. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
5. Effects of RU16117, an orally active weak oestrogenic compound, in postmenopausal women.
Faure N; Labrie F; Olivier G; Tremblay M; Cloutier D; Lemay A; Ferland L; Azadian-Boulanger G; Bouton MM; Husson JM; Raynaud JP
Maturitas; 1980 Jul; 2(2):155-68. PubMed ID: 6782429
[TBL] [Abstract][Full Text] [Related]
6. Relation between plasma hormone profiles, symptoms, and response to oestrogen treatment in women approaching the menopause.
Chakravarti S; Collins WP; Thom MH; Studd JW
Br Med J; 1979 Apr; 1(6169):983-5. PubMed ID: 219937
[TBL] [Abstract][Full Text] [Related]
7. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
8. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea.
Jeppsson S; Johansson ED; Ljungberg O; Sjöberg NO
Acta Obstet Gynecol Scand; 1977; 56(1):43-8. PubMed ID: 842303
[TBL] [Abstract][Full Text] [Related]
9. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses.
Antoniou G; Kalogirou D; Karakitsos P; Antoniou D; Kalogirou O; Giannikos L
Maturitas; 1997 Mar; 26(2):103-11. PubMed ID: 9089559
[TBL] [Abstract][Full Text] [Related]
10. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential.
Greene KE; Kettel LM; Yen SS
Fertil Steril; 1992 Aug; 58(2):338-43. PubMed ID: 1633899
[TBL] [Abstract][Full Text] [Related]
11. Treatment of climacteric and postmenopausal women with 17-beta-oestradiol and norethisterone acetate.
Furuhjelm M; Carlström K
Acta Obstet Gynecol Scand; 1977; 56(4):351-61. PubMed ID: 602703
[TBL] [Abstract][Full Text] [Related]
12. Levels of follicle-stimulating hormone, luteinizing hormone, oestradiol-17 beta and progesterone, and follicular growth in the pseudopregnant rat.
Welschen R; Osman P; Dullaart J; de Greef WJ; Uilenbroek JT; de Jong FH
J Endocrinol; 1975 Jan; 64(1):37-47. PubMed ID: 1167896
[TBL] [Abstract][Full Text] [Related]
13. The effect of a synthetic progestogen, ethylnorgestrienone, on hypothalamic-pituitary-ovarian function, cervical mucus, vaginal cytology, and endometrial morphology.
Niaraki MA; Moghissi KS; Borin K
Fertil Steril; 1981 Mar; 35(3):284-8. PubMed ID: 6781938
[TBL] [Abstract][Full Text] [Related]
14. Influence of low dose oestrogen on circulating prolactin. LH and FSH levels in post-menopausal women.
Robyn C; Vekemans M
Acta Endocrinol (Copenh); 1976 Sep; 83(1):9-14. PubMed ID: 989226
[TBL] [Abstract][Full Text] [Related]
15. [Effect of the steroid sex hormones on the LH and FSH responses to LHRH in the normal subject].
Lemarchand-Béraud T; Reymond M; Rappoport G; Magrini G; Gomez J
Pathol Biol (Paris); 1975 Dec; 23(10):917-22. PubMed ID: 772543
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
[TBL] [Abstract][Full Text] [Related]
17. Temporal relationships between ovulation and defined changes in the concentration of plasma estradiol-17 beta, luteinizing hormone, follicle-stimulating hormone, and progesterone. I. Probit analysis. World Health Organization, Task Force on Methods for the Determination of the Fertile Period, Special Programme of Research, Development and Research Training in Human Reproduction.
Am J Obstet Gynecol; 1980 Oct; 138(4):383-90. PubMed ID: 6775535
[TBL] [Abstract][Full Text] [Related]
18. Hormone serum levels and hormone receptor contents of endometria in women with normal menstrual cycles and patients bearing endometrial carcinoma.
Spona J; Ulm R; Bieglmayer C; Husslein P
Gynecol Obstet Invest; 1979; 10(2-3):71-80. PubMed ID: 535775
[TBL] [Abstract][Full Text] [Related]
19. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
20. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
Rossmanith WG; Steffens D; Schramm G
Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
